Efficacy and Human Safety of Microneedle Patches Containing Cannabidiol (YC-2106) from Cannabis sativa in Treating Inflammatory Diseases

• DOI: 10.20402/ajbc.2025.0001
• Publication Date: 2025-03-27T00:58:19Z
• Authors: Kun Hee Park; Aeri Song; Sinhwa Baek; Cho I Park; Sang Jin Park; Hwanki Ho; Kyung Mook Kang; Jeong Eun Lee; Hyeon Ha Roh; Jung Yeon Noh; Hyun-Je Park
• Keywords: Cannabis sativa

Purpose: In this study, a microneedle patch (MNP) containing cannabidiol (CBD, YC-2106) was produced, and its efficacy evaluated for human safety the treatment of inflammatory diseases. Methods: First, MNPs 0%, 1%, 3% were prepared. To evaluate anti-inflammatory efficacy, skin tissue model (KeraSkin™) purchased, culture medium collected 24 h 48 after MNP attachment, expression interleukin-8 (IL-8) compared analyzed. A primary dermal irritation test performed by requesting SGS certification in United States, where an attached to 32 participants, attachment site checked 96 confirm occurrence side effects. Results: No significant decrease IL-8 observed lipopolysaccharide (LPS)-induced inflammation. However, h, significantly inhibited group treated with 1% CBD. test, no effects any participants; therefore, confirmed percutaneous phase. Conclusion: The CBD-MNP is effective treating diseases through inhibition exhibits high potential as drug treatment, which safe use body.